TY - JOUR PY - 2007 DA - 2007// TI - Guidelines for the diagnosis and Management of Asthma-Summary Report 2007 JO - J Allergy Clin Immunol VL - 120 UR - https://doi.org/10.1016/j.jaci.2007.09.029 DO - 10.1016/j.jaci.2007.09.029 ID - ref1 ER - TY - JOUR AU - Stokes, J. R. AU - Casale, T. B. PY - 2016 DA - 2016// TI - Characterization of asthma endotypes: implications for therapy JO - Ann Allergy Asthma Immunol VL - 117 UR - https://doi.org/10.1016/j.anai.2016.05.016 DO - 10.1016/j.anai.2016.05.016 ID - Stokes2016 ER - TY - JOUR AU - Wenzel, S. E. PY - 2012 DA - 2012// TI - Asthma phenotypes: the evolution from clinical to molecular approaches JO - Nat Med VL - 18 UR - https://doi.org/10.1038/nm.2678 DO - 10.1038/nm.2678 ID - Wenzel2012 ER - TY - JOUR AU - Casale, T. B. PY - 2017 DA - 2017// TI - Biologics and biomarkers for asthma, urticaria, and nasal polyposis JO - J Allergy Clin Immunol VL - 139 UR - https://doi.org/10.1016/j.jaci.2017.03.006 DO - 10.1016/j.jaci.2017.03.006 ID - Casale2017 ER - TY - JOUR AU - Berry, A. AU - Busse, W. W. PY - 2016 DA - 2016// TI - Biomarkers in asthmatic patients: has their time come to direct treatment? JO - J Allergy Clin Immunol VL - 137 UR - https://doi.org/10.1016/j.jaci.2016.03.009 DO - 10.1016/j.jaci.2016.03.009 ID - Berry2016 ER - TY - JOUR AU - Hanania, N. A. PY - 2013 DA - 2013// TI - Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study JO - Am J Respir Crit Care Med VL - 187 UR - https://doi.org/10.1164/rccm.201208-1414OC DO - 10.1164/rccm.201208-1414OC ID - Hanania2013 ER - TY - JOUR AU - Busse, W. AU - Spector, S. AU - Rosén, K. AU - Wang, Y. AU - Alpan, O. PY - 2013 DA - 2013// TI - High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects JO - J Allergy Clin Immunol VL - 132 UR - https://doi.org/10.1016/j.jaci.2013.02.032 DO - 10.1016/j.jaci.2013.02.032 ID - Busse2013 ER - TY - JOUR AU - Casale, T. B. AU - Chipps, B. E. AU - Rosén, K. AU - Trzaskoma, B. AU - Haselkorn, T. AU - Omachi, T. A. AU - Greenberg, S. AU - Hanania, N. A. PY - 2017 DA - 2017// TI - Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma JO - Allergy VL - 73 UR - https://doi.org/10.1111/all.13302 DO - 10.1111/all.13302 ID - Casale2017 ER - TY - JOUR AU - Chipps, B. E. PY - 2017 DA - 2017// TI - Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience JO - J Allergy Clin Immunol VL - 139 UR - https://doi.org/10.1016/j.jaci.2017.03.002 DO - 10.1016/j.jaci.2017.03.002 ID - Chipps2017 ER - TY - JOUR AU - Nair, P. PY - 2009 DA - 2009// TI - Mepolizumab for prednisone-dependent asthma with sputum eosinophilia JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0805435 DO - 10.1056/NEJMoa0805435 ID - Nair2009 ER - TY - JOUR AU - Pavord, I. D. PY - 2012 DA - 2012// TI - Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60988-X DO - 10.1016/S0140-6736(12)60988-X ID - Pavord2012 ER - TY - JOUR AU - Bel, E. H. PY - 2014 DA - 2014// TI - Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403291 DO - 10.1056/NEJMoa1403291 ID - Bel2014 ER - TY - JOUR AU - Ortega, H. G. PY - 2014 DA - 2014// TI - Mepolizumab treatment in patients with severe eosinophilic asthma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403290 DO - 10.1056/NEJMoa1403290 ID - Ortega2014 ER - TY - JOUR AU - Liu, Y. AU - Zhang, S. AU - Li, D. -. W. AU - Jiang, S. -. J. PY - 2013 DA - 2013// TI - Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0059872 DO - 10.1371/journal.pone.0059872 ID - Liu2013 ER - TY - JOUR AU - Castro, M. PY - 2011 DA - 2011// TI - Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study JO - Am J Respir Crit Care Med VL - 184 UR - https://doi.org/10.1164/rccm.201103-0396OC DO - 10.1164/rccm.201103-0396OC ID - Castro2011 ER - TY - JOUR AU - Castro, M. PY - 2015 DA - 2015// TI - Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00042-9 DO - 10.1016/S2213-2600(15)00042-9 ID - Castro2015 ER - TY - JOUR AU - Corren, J. AU - Weinstein, S. AU - Janka, L. AU - Zangrilli, J. AU - Garin, M. PY - 2016 DA - 2016// TI - Phase 3 study of Reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts JO - Chest VL - 150 UR - https://doi.org/10.1016/j.chest.2016.03.018 DO - 10.1016/j.chest.2016.03.018 ID - Corren2016 ER - TY - JOUR AU - Castro, M. PY - 2014 DA - 2014// TI - Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study JO - Lancet Respir Med VL - 2 UR - https://doi.org/10.1016/S2213-2600(14)70201-2 DO - 10.1016/S2213-2600(14)70201-2 ID - Castro2014 ER - TY - JOUR AU - FitzGerald, J. M. PY - 2016 DA - 2016// TI - Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31322-8 DO - 10.1016/S0140-6736(16)31322-8 ID - FitzGerald2016 ER - TY - JOUR AU - Bleecker, E. R. PY - 2016 DA - 2016// TI - Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31324-1 DO - 10.1016/S0140-6736(16)31324-1 ID - Bleecker2016 ER - TY - JOUR AU - Nowak, R. M. PY - 2015 DA - 2015// TI - A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma JO - Am J Emerg Med VL - 33 UR - https://doi.org/10.1016/j.ajem.2014.09.036 DO - 10.1016/j.ajem.2014.09.036 ID - Nowak2015 ER - TY - JOUR AU - Wenzel, S. PY - 2013 DA - 2013// TI - Dupilumab in persistent asthma with elevated eosinophil levels JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1304048 DO - 10.1056/NEJMoa1304048 ID - Wenzel2013 ER - TY - JOUR AU - Wenzel, S. PY - 2016 DA - 2016// TI - Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)30307-5 DO - 10.1016/S0140-6736(16)30307-5 ID - Wenzel2016 ER - TY - JOUR AU - Castro, M. PY - 2018 DA - 2018// TI - Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1804092 DO - 10.1056/NEJMoa1804092 ID - Castro2018 ER - TY - JOUR AU - Rabe, K. F. PY - 2018 DA - 2018// TI - Efficacy and safety of Dupilumab in glucocorticoid-dependent severe asthma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1804093 DO - 10.1056/NEJMoa1804093 ID - Rabe2018 ER - TY - JOUR AU - Gallelli, L. AU - Busceti, M. T. AU - Vatrella, A. AU - Maselli, R. AU - Pelaia, G. PY - 2013 DA - 2013// TI - Update on anticytokine treatment for asthma JO - Biomed Res Int VL - 2013 UR - https://doi.org/10.1155/2013/104315 DO - 10.1155/2013/104315 ID - Gallelli2013 ER - TY - JOUR AU - Corren, J. PY - 2011 DA - 2011// TI - Lebrikizumab treatment in adults with asthma JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1106469 DO - 10.1056/NEJMoa1106469 ID - Corren2011 ER - TY - JOUR AU - Hanania, N. A. PY - 2016 DA - 2016// TI - Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials JO - Lancet Respir Med VL - 4 UR - https://doi.org/10.1016/S2213-2600(16)30265-X DO - 10.1016/S2213-2600(16)30265-X ID - Hanania2016 ER - TY - JOUR AU - Brightling, C. E. PY - 2015 DA - 2015// TI - Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00197-6 DO - 10.1016/S2213-2600(15)00197-6 ID - Brightling2015 ER - TY - JOUR AU - Farne, H. AU - Jackson, D. J. AU - Johnston, S. L. PY - 2016 DA - 2016// TI - Are emerging PGD2 antagonists a promising therapy class for treating asthma? JO - Expert Opin Emerg Drugs VL - 21 UR - https://doi.org/10.1080/14728214.2016.1244262 DO - 10.1080/14728214.2016.1244262 ID - Farne2016 ER - TY - JOUR AU - Barnes, N. PY - 2012 DA - 2012// TI - A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma JO - Clin Exp Allergy VL - 42 UR - https://doi.org/10.1111/j.1365-2222.2011.03813.x DO - 10.1111/j.1365-2222.2011.03813.x ID - Barnes2012 ER - TY - JOUR AU - Pettipher, R. PY - 2014 DA - 2014// TI - Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459 JO - Allergy VL - 69 UR - https://doi.org/10.1111/all.12451 DO - 10.1111/all.12451 ID - Pettipher2014 ER - TY - JOUR AU - Singh, D. PY - 2013 DA - 2013// TI - Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 JO - Eur Respir J VL - 41 UR - https://doi.org/10.1183/09031936.00092111 DO - 10.1183/09031936.00092111 ID - Singh2013 ER - TY - JOUR AU - Wenzel, S. AU - Hopkins, R. AU - Saunders, M. AU - Chantry, D. AU - Anderson, L. AU - Aitchison, R. AU - Eberhardt, C. AU - Bell, S. AU - Cole, J. AU - Wolfe, J. D. AU - Spector, S. PY - 2014 DA - 2014// TI - Safety and efficacy of ARRY-502, a potent, selective, Oral CRTh2 antagonist, in patients with mild to moderate Th2-driven asthma JO - J Allergy Clin Immunol VL - 133 UR - https://doi.org/10.1016/j.jaci.2013.12.037 DO - 10.1016/j.jaci.2013.12.037 ID - Wenzel2014 ER - TY - JOUR AU - Hall, I. P. PY - 2015 DA - 2015// TI - Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment JO - Pulm Pharmacol Ther VL - 32 UR - https://doi.org/10.1016/j.pupt.2015.03.003 DO - 10.1016/j.pupt.2015.03.003 ID - Hall2015 ER - TY - JOUR AU - Miller, D. PY - 2017 DA - 2017// TI - A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma JO - Allergy Asthma Proc VL - 38 UR - https://doi.org/10.2500/aap.2017.38.4034 DO - 10.2500/aap.2017.38.4034 ID - Miller2017 ER - TY - JOUR AU - Erpenbeck, V. J. PY - 2016 DA - 2016// TI - The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma JO - Pulm Pharmacol Ther VL - 39 UR - https://doi.org/10.1016/j.pupt.2016.06.005 DO - 10.1016/j.pupt.2016.06.005 ID - Erpenbeck2016 ER - TY - JOUR AU - Bateman, E. D. PY - 2017 DA - 2017// TI - Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids JO - Eur Respir J VL - 50 UR - https://doi.org/10.1183/13993003.00670-2017 DO - 10.1183/13993003.00670-2017 ID - Bateman2017 ER - TY - JOUR AU - Gonem, S. PY - 2016 DA - 2016// TI - Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-Centre, randomised, double-blind, parallel-group, placebo-controlled trial JO - Lancet Respir Med VL - 4 UR - https://doi.org/10.1016/S2213-2600(16)30179-5 DO - 10.1016/S2213-2600(16)30179-5 ID - Gonem2016 ER - TY - JOUR AU - Busse, W. W. PY - 2013 DA - 2013// TI - Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients JO - J Allergy Clin Immunol VL - 131 UR - https://doi.org/10.1016/j.jaci.2012.10.013 DO - 10.1016/j.jaci.2012.10.013 ID - Busse2013 ER - TY - JOUR AU - Diamant, Z. PY - 2014 DA - 2014// TI - Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics JO - Clin Exp Allergy VL - 44 UR - https://doi.org/10.1111/cea.12357 DO - 10.1111/cea.12357 ID - Diamant2014 ER - TY - STD TI - Ziegler, AF. "The Biology of Thymic Stromal Lymphopoietin (TSLP)." Immunopharmacology. Ed. David R. Webb. San Diego: Elsevier; 2013. 129–156. ID - ref42 ER - TY - JOUR AU - Allakhverdi, Z. PY - 2007 DA - 2007// TI - Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells JO - J Exp Med VL - 204 UR - https://doi.org/10.1084/jem.20062211 DO - 10.1084/jem.20062211 ID - Allakhverdi2007 ER - TY - JOUR AU - Soumelis, V. PY - 2002 DA - 2002// TI - Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP JO - Nat Immunol VL - 3 UR - https://doi.org/10.1038/ni805 DO - 10.1038/ni805 ID - Soumelis2002 ER - TY - JOUR AU - Ying, S. PY - 2008 DA - 2008// TI - Expression and cellular provenance of Thymic stromal Lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease JO - J Immunol VL - 181 UR - https://doi.org/10.4049/jimmunol.181.4.2790 DO - 10.4049/jimmunol.181.4.2790 ID - Ying2008 ER - TY - JOUR AU - Ying, S. PY - 2005 DA - 2005// TI - Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity JO - J Immunol VL - 174 UR - https://doi.org/10.4049/jimmunol.174.12.8183 DO - 10.4049/jimmunol.174.12.8183 ID - Ying2005 ER - TY - JOUR AU - Harada, M. PY - 2011 DA - 2011// TI - Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma JO - Am J Respir Cell Mol Biol VL - 44 UR - https://doi.org/10.1165/rcmb.2009-0418OC DO - 10.1165/rcmb.2009-0418OC ID - Harada2011 ER - TY - JOUR AU - Gauvreau, G. M. PY - 2014 DA - 2014// TI - Effects of an anti-TSLP antibody on allergen-induced asthmatic responses JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1402895 DO - 10.1056/NEJMoa1402895 ID - Gauvreau2014 ER - TY - JOUR AU - Corren, J. PY - 2017 DA - 2017// TI - Tezepelumab in adults with uncontrolled asthma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1704064 DO - 10.1056/NEJMoa1704064 ID - Corren2017 ER - TY - JOUR AU - Kouzaki, H. AU - Tojima, I. AU - Kita, H. AU - Shimizu, T. PY - 2013 DA - 2013// TI - Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells JO - Am J Respir Cell Mol Biol VL - 49 UR - https://doi.org/10.1165/rcmb.2012-0304OC DO - 10.1165/rcmb.2012-0304OC ID - Kouzaki2013 ER - TY - JOUR AU - Hurst, S. D. PY - 2002 DA - 2002// TI - New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25 JO - J Immunol VL - 169 UR - https://doi.org/10.4049/jimmunol.169.1.443 DO - 10.4049/jimmunol.169.1.443 ID - Hurst2002 ER - TY - JOUR AU - Tang, W. PY - 2014 DA - 2014// TI - IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma JO - Int Arch Allergy Immunol VL - 163 UR - https://doi.org/10.1159/000355331 DO - 10.1159/000355331 ID - Tang2014 ER - TY - JOUR AU - Cheng, D. PY - 2014 DA - 2014// TI - Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma JO - Am J Respir Crit Care Med VL - 190 UR - https://doi.org/10.1164/rccm.201403-0505OC DO - 10.1164/rccm.201403-0505OC ID - Cheng2014 ER - TY - JOUR AU - Willis, C. R. PY - 2015 DA - 2015// TI - IL-17RA signaling in airway inflammation and bronchial Hyperreactivity in allergic asthma JO - Am J Respir Cell Mol Biol VL - 53 UR - https://doi.org/10.1165/rcmb.2015-0038OC DO - 10.1165/rcmb.2015-0038OC ID - Willis2015 ER - TY - JOUR AU - Mitchell, P. D. AU - O'Byrne, P. M. PY - 2017 DA - 2017// TI - Epithelial-derived cytokines in asthma JO - Chest VL - 151 UR - https://doi.org/10.1016/j.chest.2016.10.042 DO - 10.1016/j.chest.2016.10.042 ID - Mitchell2017 ER - TY - JOUR AU - Smith, S. G. PY - 2016 DA - 2016// TI - Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia JO - J Allergy Clin Immunol VL - 137 UR - https://doi.org/10.1016/j.jaci.2015.05.037 DO - 10.1016/j.jaci.2015.05.037 ID - Smith2016 ER - TY - JOUR AU - Kamijo, S. PY - 2013 DA - 2013// TI - IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation JO - J Immunol VL - 190 ID - Kamijo2013 ER - TY - STD TI - Han H, Ziegler SF. Intradermal administration of IL-33 induces allergic airway inflammation. Sci Rep. 2017;7(1706):1–8. ID - ref58 ER - TY - JOUR AU - Mizutani, N. AU - Nabe, T. AU - Yoshino, S. PY - 2013 DA - 2013// TI - Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice JO - Immunology VL - 139 UR - https://doi.org/10.1111/imm.12071 DO - 10.1111/imm.12071 ID - Mizutani2013 ER - TY - JOUR AU - Préfontaine, D. PY - 2009 DA - 2009// TI - Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells JO - J Immunol VL - 183 UR - https://doi.org/10.4049/jimmunol.0802387 DO - 10.4049/jimmunol.0802387 ID - Préfontaine2009 ER - TY - JOUR AU - Wang, Y. AU - Wang, L. AU - Hua, S. PY - 2017 DA - 2017// TI - Interleukin-33 in children with asthma: a systematic review and meta-analysis JO - Allergol Immunopathol (Madr) VL - 45 UR - https://doi.org/10.1016/j.aller.2016.12.007 DO - 10.1016/j.aller.2016.12.007 ID - Wang2017 ER - TY - JOUR AU - Fogli, L. K. PY - 2013 DA - 2013// TI - T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia JO - J Immunol VL - 191 UR - https://doi.org/10.4049/jimmunol.1301360 DO - 10.4049/jimmunol.1301360 ID - Fogli2013 ER - TY - JOUR AU - Molet, S. PY - 2001 DA - 2001// TI - IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines JO - J Allergy Clin Immunol VL - 108 UR - https://doi.org/10.1067/mai.2001.117929 DO - 10.1067/mai.2001.117929 ID - Molet2001 ER - TY - JOUR AU - Al-Ramli, W. PY - 2009 DA - 2009// TI - T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma JO - J Allergy Clin Immunol VL - 123 UR - https://doi.org/10.1016/j.jaci.2009.02.024 DO - 10.1016/j.jaci.2009.02.024 ID - Al-Ramli2009 ER - TY - JOUR AU - Sergejeva, S. AU - Ivanov, S. AU - Lötvall, J. AU - Lindén, A. PY - 2005 DA - 2005// TI - Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation JO - Am J Respir Cell Mol Biol VL - 33 UR - https://doi.org/10.1165/rcmb.2004-0213OC DO - 10.1165/rcmb.2004-0213OC ID - Sergejeva2005 ER - TY - JOUR AU - Kudo, M. PY - 2012 DA - 2012// TI - IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction JO - Nat Med VL - 18 UR - https://doi.org/10.1038/nm.2684 DO - 10.1038/nm.2684 ID - Kudo2012 ER - TY - JOUR AU - Busse, W. W. PY - 2013 DA - 2013// TI - Randomized, double-blind, placebo-controlled study of Brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma JO - Am J Respir Crit Care Med VL - 188 UR - https://doi.org/10.1164/rccm.201212-2318OC DO - 10.1164/rccm.201212-2318OC ID - Busse2013 ER - TY - JOUR AU - Kirsten, A. PY - 2013 DA - 2013// TI - The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers JO - Eur Respir J VL - 41 UR - https://doi.org/10.1183/09031936.00123612 DO - 10.1183/09031936.00123612 ID - Kirsten2013 ER - TY - STD TI - Clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01478360?term=secukinumab&cond=Asthma&rank=1. (Accessed 7 Aug 2018). UR - https://clinicaltrials.gov/ct2/show/results/NCT01478360?cond=AIN457&draw=2&rank=13§=X437156#part ID - ref69 ER - TY - JOUR AU - Mukaida, N. PY - 2003 DA - 2003// TI - Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases JO - Am J Physiol Lung Cell Mol Physiol VL - 284 UR - https://doi.org/10.1152/ajplung.00233.2002 DO - 10.1152/ajplung.00233.2002 ID - Mukaida2003 ER - TY - JOUR AU - Chapman, R. W. PY - 2009 DA - 2009// TI - CXCR2 antagonists for the treatment of pulmonary disease JO - Pharmacol Ther VL - 121 UR - https://doi.org/10.1016/j.pharmthera.2008.10.005 DO - 10.1016/j.pharmthera.2008.10.005 ID - Chapman2009 ER - TY - JOUR AU - Chapman, R. W. PY - 2007 DA - 2007// TI - A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation JO - J Pharmacol Exp Ther VL - 322 UR - https://doi.org/10.1124/jpet.106.119040 DO - 10.1124/jpet.106.119040 ID - Chapman2007 ER - TY - JOUR AU - Nair, P. PY - 2012 DA - 2012// TI - Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial JO - Clin Exp Allergy VL - 42 UR - https://doi.org/10.1111/j.1365-2222.2012.04014.x DO - 10.1111/j.1365-2222.2012.04014.x ID - Nair2012 ER - TY - JOUR AU - O'Byrne, P. M. PY - 2016 DA - 2016// TI - Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial JO - Lancet Respir Med VL - 4 UR - https://doi.org/10.1016/S2213-2600(16)30227-2 DO - 10.1016/S2213-2600(16)30227-2 ID - O'Byrne2016 ER - TY - JOUR AU - Webb, D. C. PY - 2000 DA - 2000// TI - Integrated signals between IL-13, IL-4, and IL-5 regulate airways Hyperreactivity JO - J Immunol VL - 165 UR - https://doi.org/10.4049/jimmunol.165.1.108 DO - 10.4049/jimmunol.165.1.108 ID - Webb2000 ER -